GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company’s website, under the Investors tab. Details are as follows:
GlycoMimtics，Inc.。纳斯达克股票代码：GERC)今天宣布，该公司的高管计划参加3月份的三个虚拟医疗会议。有关演讲和小组讨论的更多信息可在公司网站的投资者选项卡下获得。详情如下：
Cowen 41st Annual Health Care Conference
考恩第41届卫生保健年会
March 1 – March 4, 2021
2021年3月1日-3月4日
Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in Leukemias Panel
埃里克·费尔德曼(Eric Feldman)，医学博士，糖仿制学临床开发部副总裁，将参加白血病小组
Wed, March 3, 2021, 11:40 a.m. – 12:40 p.m. (EST)
星期三，2021年3月3日上午11：40-下午12：40(EST)
Access to the panel discussion is for registered attendees only.
只有已注册的与会者才能参加小组讨论。
H.C. Wainwright Global Life Sciences Conference
H.C.温赖特全球生命科学大会
March 9 – 10, 2021
2021年3月9日至10日
Rachel King, GlycoMimetics CEO, to present a corporate overview
GlycoMimtics首席执行官雷切尔·金介绍公司概况
The presentation will be available on-demand, beginning at 7 a.m. ET, March 9 through March 10. Access will be provided through the Company’s website (Investors section) and archived for 90 days.
演示文稿将于上午7点开始按需提供。美国东部时间3月9日至3月10日。访问将通过公司网站(投资者部分)提供，并存档90天。
33rd Annual Virtual Roth Conference
第33届虚拟罗斯年会
March 15 – 17, 2021
2021年3月15日至17日
Rachel King, GlycoMimetics CEO, to present a corporate overview
GlycoMimtics首席执行官雷切尔·金介绍公司概况
Mon, March 15, 10:00 a.m. – 12:00 p.m. (EST) in Virtual 2 (Panel: Navigating Clinical Development in Rare Hematology & Inflammatory Disease). A link to the panel session will be available in the Investors section of the GlycoMimetics website.
星期一，3月15日，上午10：00-下午12点(EST)in Virtual 2(专题讨论：导航罕见血液病和炎症性疾病的临床发展)。GlycoMimtics网站的投资者部分将提供小组会议的链接。
About GlycoMimetics, Inc.
关于GlycoMimtics公司
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics’ drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com .
GlycoMimtics是一家生物技术公司，专注于血液肿瘤学和一系列新型仿糖药物的流水线，所有这些药物都是为了解决因碳水化合物生物学起关键作用的疾病而导致的未得到满足的医疗需求。GlycoMimtics的候选药物uproleselan是一种E-选择素拮抗剂，在1/2期临床试验中作为治疗急性髓细胞白血病的潜在方法进行了评估，目前正在一系列患者中进行评估，其中包括公司赞助的突破性治疗指定的复发/难治性急性髓细胞白血病的3期试验。Rivipansel是一种泛选择素拮抗剂，正在探索用于治疗镰状细胞疾病的急性VOC。GlycoMimtics还完成了与另一种全资候选药物GMI-1359的一期临床试验，GMI-1359是一种CXCR4和E-选择素联合拮抗剂。GlycoMimtics公司位于马里兰州罗克维尔，位于生物健康首都地区。欲了解更多信息，请访问www.garcomimetics.com。
译文内容由第三方软件翻译。